EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System

Maria Antonietta Barbieri iD, Emanuela Elisa Sorbara, Giulia Russo, Giuseppe Cicala iD, Tindara Franchina, Mariacarmela Santarpia, Nicola Silvestris, Edoardo Spina iD

Cancers · 20.03.2023 · 15 (6) · 1851

DOI: 10.3390/cancers15061851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.03.2023. Verfasst von Maria Antonietta Barbieri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors (TKIs) are widely used in gastrointestinal stromal tumors (GISTs). The aim of this study is to evaluate the reporting frequency of neuropsychiatric adverse drug reactions (ADRs) for TKIs through the analysis of European individual case safety reports (ICSRs). All ICSRs collected in EudraVigilance up to 31 December 2021 with one TKI having GISTs as an indication (imatinib (IM), sunitinib (SU), avapritinib (AVA), regorafenib (REG), and ripretinib (RIP)) were included. A disproportionality analysis was performed to assess the frequency of reporting for each TKI compared to all other TKIs. The number of analyzed ICSRs was 8512, of which 57.9% were related to IM. Neuropsychiatric ADRs were reported at least once in 1511 ICSRs (17.8%). A higher reporting probability of neuropsychiatric ADRs was shown for AVA. Most neuropsychiatric ADRs were known, except for a higher frequency of lumbar spinal cord and nerve root disorders (reporting odds ratio, ROR 4.46; confidence interval, CI 95% 1.58–12.54), olfactory nerve disorders (8.02; 2.44–26.33), and hallucinations (22.96; 8.45–62.36) for AVA. The analyses of European ICSRs largely confirmed the safety profiles of TKIs in GISTs, but some ADRs are worthy of discussion. Further studies are needed to increase the knowledge of the neuropsychiatric disorders of newly approved TKIs.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactionsgastrointestinal stromal tumorsneuropsychiatric disorderssafety monitoringtyrosine kinase inhibitors (TKI)

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
  • Department of Human Pathology in Adulthood and Childhood Gaetano Barresi, University of Messina, 98125 Messina, Italy.

ORCID-Profile: Maria Antonietta Barbieri, Giuseppe Cicala, Edoardo Spina

Zitieren

APA

Barbieri, M. A., Sorbara, E. E., Russo, G., Cicala, G., Franchina, T., Santarpia, M., Silvestris, N., & Spina, E. (2023). Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System. Cancers, 15(6), 1851. https://doi.org/10.3390/cancers15061851

Vancouver

Barbieri MA, Sorbara EE, Russo G, Cicala G, Franchina T, Santarpia M, et al. Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System. Cancers. 2023;15(6):1851. doi:10.3390/cancers15061851

BibTeX
@article{Barbieri2023,
  author = {Barbieri, Maria Antonietta and Sorbara, Emanuela Elisa and Russo, Giulia and Cicala, Giuseppe and Franchina, Tindara and Santarpia, Mariacarmela and Silvestris, Nicola and Spina, Edoardo},
  title = {Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1851},
  doi = {10.3390/cancers15061851}
}
Kostenlos starten →